Crohn's Disease

In 2023, there have already been several updates to guidelines and recommendations in gastroenterology care from ACG and AGA, including managing celiac disease, acute lower GI bleeding, ulcerative colitis and diagnosing biliary strictures.

Many barriers to care persist among South Asian patients with inflammatory bowel disease; to combat the unique challenges of this population, South Asian IBD Alliance seeks to increase preventive research and access to care.

The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, according to a press release from the manufacturer.

With recent data highlighting the emotional and social challenges of inflammatory bowel disease, AGA has launched the “My IBD Life” campaign to address the growing need for psychosocial support in patient care.

In a Healio video exclusive, Maria T. Abreu, MD, outlined long-term data presented at the European Crohn’s and Colitis Congress on the use of Stelara among patients with inflammatory bowel disease.

Travel may no longer be daunting for patients with inflammatory bowel disease, thanks to a “one-stop travel advice” website that offers key resources, support and access to a comprehensive network of IBD specialists worldwide.

In a Healio video exclusive, Remo Panaccione, MD, noted the cumulative benefit of Skyrizi and Rinvoq for the induction and maintenance treatment of patients with inflammatory bowel disease.

In this Healio video exclusive, Parakkal Deepak, MBBS, MS, FACG, highlights several challenges faced by individuals with inflammatory bowel disease in South Asia, including an “inadequate availability” of IBD specialists.

Increasing adalimumab dose intervals reduced infection-related adverse events and costs in patients with Crohn’s disease, but also resulted in lower remission rates, researchers reported in The Lancet Gastroenterology & Hepatology.

In this Healio video exclusive, Neilanjan Nandi, MD, FACP, discusses the financial burden for patients with inflammatory bowel disease in South Asia, fueled by costly diagnostics and treatments and lack of health insurance.